✦ LIBER ✦

DOP061 Pharmacokinetic considerations for optimising dosing regimens of infliximab in patients with Crohn's disease

✍ Scribed by Andersson, H.; Keunecke, A.; Eser, A.; Huisinga, W.; Reinisch, W.; Kloft, C.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

DOP063 Biomarker panel for prediction of

✍ de Bruyn, M.; Bessissow, T.; Billiet, T.; Cleynen, I.; Kirkland, R.; Liu, X.; Ha 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 103 KB

Three dose induction regimen of inflixim

✍ Lloyd Mayer; Chenlong Han; Mohan Bala; Greg Keenan; Allan Olson; Stephen B Hanau 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 30 KB

P352 Need for infliximab dose intensific

✍ C. Taxonera; D. Olivares; J.L. Mendoza; M. Cañas; F. Estremera; M. Díaz-Rubio 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 61 KB

Infliximab for the treatment of fistulas

✍ Elena Ricart; William J. Sandborn 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 82 KB

P397 Outcomes after dose escalation of i

✍ Sako, M.; Kawaguchi, T.; Hirayama, A.; Fukushi, G.; Hayama, K.; Fujiwara, T.; Yo 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 51 KB

P016 FLEXIBILITY IN INTERVAL AND DOSING

✍ F. Schnitzler; H. Fidder; M. Ferrante; M. Noman; G. Van Assche; I. Hoffman; S. V 📂 Article 📅 2008 🏛 Oxford University Press ⚖ 66 KB